CBIC Updated CIC Exam Questions and Answers by shanaya

A safety culture withreciprocal accountabilityemphasizes mutual responsibility for maintaining safe practices, encouraging staff at all levels to "speak up" or "stop the line" when they observe risky practices. This concept reflects a learning organization and a just culture that supports open communication and proactive risk mitigation.

According to theAPIC Text, a strong safety culture is described as one where:

“The leadership can expect staff members to call out or stop the line when they see risk, and staff can expect leadership to listen and act.”

This dynamic reflects reciprocal accountability.

Other options are less accurate:

A. Human factorsrefer to system design, not behavioral accountability.

B. Honest disclosure of a safety eventis about post-event transparency, not real-time intervention.

C. A blaming and shaming cultureis antithetical to safety culture principles.

The Chi-square test is the most appropriate test for comparing infection rates (categorical data) before and after an intervention​.

CBIC Infection Control References:

CIC Study Guide, "Statistical Analysis in Infection Control," Chapter 5​.

The pneumococcal vaccine is designed to protect against infections caused by Streptococcus pneumoniae, a bacterium responsible for diseases such as pneumonia, meningitis, and bacteremia. The appropriateness of this vaccine depends on the population's risk profile, particularly their susceptibility to invasive pneumococcal disease (IPD). The Certification Board of Infection Control and Epidemiology (CBIC) highlights the role of infection preventionists as educators in promoting vaccination as a key risk reduction strategy, aligning with the "Education and Training" domain (CBIC Practice Analysis, 2022). The Centers for Disease Control and Prevention (CDC) provides specific guidelines on pneumococcal vaccination, recommending it for individuals at higher risk due to underlying medical conditions or immunologic status.

Option A, asplenic patients, refers to individuals who have had their spleen removed (e.g., due to trauma or disease) or have a nonfunctional spleen (e.g., in sickle cell disease). The spleen plays a critical role in clearing encapsulated bacteria like Streptococcus pneumoniae from the bloodstream. Without a functioning spleen, these patients are at significantly increased risk of overwhelming post-splenectomy infection (OPSI), with pneumococcal disease being a leading cause. The CDC and Advisory Committee on Immunization Practices (ACIP) strongly recommend pneumococcal vaccination, including both PCV15/PCV20 and PPSV23, for asplenic patients, making this group the most appropriate for the vaccine in this context. The infection preventionist should prioritize educating these patients and their families about the vaccine's importance and timing.

Option B, international travelers, may benefit from various vaccines depending on their destination (e.g., yellow fever or typhoid), but pneumococcal vaccination is not routinely recommended unless they have specific risk factors (e.g., asplenia or chronic illness) or are traveling to areas with high pneumococcal disease prevalence. This group is not inherently a priority for pneumococcal vaccination. Option C, immunocompromised newborns, includes infants with congenital immunodeficiencies or other conditions, who may indeed require pneumococcal vaccination as part of their routine immunization schedule (e.g., PCV15 or PCV20 starting at 2 months). However, newborns are generally covered under universal childhood vaccination programs, and the question’s focus on "MOST appropriate" suggests a group with a more specific, elevated risk, which asplenic patients fulfill. Option D, patients in behavioral health settings, may have varied health statuses, but this group is not specifically targeted for pneumococcal vaccination unless they have additional risk factors (e.g., chronic diseases), making it less appropriate than asplenic patients.

The CBIC emphasizes tailoring education to high-risk populations, and the CDC’s Adult and Pediatric Immunization Schedules (2023) identify asplenic individuals as a top priority for pneumococcal vaccination due to their extreme vulnerability. Thus, the infection preventionist should focus on asplenic patients as the group for whom the pneumococcal vaccine is most appropriate.

The scenario involves the introduction of a new hospital disinfectant with a 3-minute contact time, intended for use across patient care areas, but with concerns raised by Environmental Services about its high cost. The infection preventionist’s advice must balance infection control efficacy with cost management, adhering to principles outlined by the Certification Board of Infection Control and Epidemiology (CBIC) and evidence-based practices. The goal is to optimize the disinfectant’s use while ensuring a safe environment. Let’s evaluate each option:

A. Use the new disinfectant for patient washrooms only: Limiting the disinfectant to patient washrooms focuses its use on high-touch, high-risk areas where pathogens (e.g., Clostridioides difficile, norovirus) may be prevalent. However, this approach restricts the disinfectant’s application to a specific area, potentially leaving other patient care surfaces (e.g., bed rails, tables) vulnerable to contamination. While cost-saving, it does not address the broad infection control needs across all patient care areas, making it an incomplete strategy.

B. Use detergents on the floors in patient rooms: Detergents are cleaning agents that remove dirt and organic material but lack the antimicrobial properties of disinfectants. Floors in patient rooms can harbor pathogens, but they are generally considered lower-risk surfaces compared to high-touch areas (e.g., bed rails, doorknobs). Using detergents instead of the new disinfectant on floors could reduce costs but compromises infection control, as floors may still contribute to environmental transmission (e.g., via shoes or equipment). This option is not optimal given the availability of an effective disinfectant.

C. Use detergents on smooth horizontal surfaces: Smooth horizontal surfaces (e.g., tables, counters, overbed tables) are common sites for pathogen accumulation and transmission in patient rooms. Using detergents to clean these surfaces removes organic material, which is acritical first step before disinfection. If the 3-minute contact time disinfectant is reserved for high-touch or high-risk surfaces (e.g., bed rails, call buttons) where disinfection is most critical, this approach maximizes the disinfectant’s efficacy while reducing its overall use and cost. This strategy aligns with CBIC guidelines, which emphasize a two-step process (cleaning followed by disinfection) and targeted use of resources, making it a practical and cost-effective recommendation.

D. Use new disinfectant for all surfaces in the patient room: Using the disinfectant on all surfaces ensures comprehensive pathogen reduction but increases consumption and cost, which is a concern for Environmental Services. While the 3-minute contact time suggests efficiency, overusing the disinfectant on low-risk surfaces (e.g., floors, walls) may not provide proportional infection control benefits and could strain the budget. This approach does not address the cost concern and is less strategic than targeting high-risk areas.

The best advice is C, using detergents on smooth horizontal surfaces to handle routine cleaning, while reserving the new disinfectant for high-touch or high-risk areas where its antimicrobial action is most needed. This optimizes infection prevention, aligns with CBIC’s emphasis on evidence-based environmental cleaning, and addresses the cost concern by reducing unnecessary disinfectant use. The infection preventionist should also recommend a risk assessment to identify priority surfaces for disinfectant application.